By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators publish new report on Silicon. According to news reporting originating in New York City, New York, by NewsRx journalists, research stated, "Gene silencing agents such as small interfering RNA (siRNA) and microRNA offer the promise to modulate expression of almost every gene for the treatment of human diseases including cancer. However, lack of vehicles for effective systemic delivery to the disease organs has greatly limited their in vivo applications."
The news reporters obtained a quote from the research from Weill Cornell Medical College, "In this study, we developed a high capacity polycation-functionalized nanoporous silicon (PCPS) platform comprised of nanoporous silicon microparticles functionalized with arginine-polyethyleneimine inside the nanopores for effective delivery of gene silencing agents. Incubation of MDA-MB-231 human breast cancer cells with PCPS loaded with STAT3 siRNA (PCPS/STAT3) or GRP78 siRNA (PCPS/GRP78) resulted in 91 and 83% reduction of STAT3 and GRP78 gene expression in vitro. Treatment of cells with a microRNA-18a mimic in PCPS (PCPS/miR-18) knocked down 90% expression of the microRNA-18a target gene ATM. Systemic delivery of PCPS/STAT3 siRNA in murine model of MDA-MB-231 breast cancer enriched particles in tumor tissues and reduced STAT3 expression in cancer cells, causing significant reduction of cancer stem cells in the residual tumor tissue. At the therapeutic dosage, PCPS/STAT3 siRNA did not trigger acute immune response in FVB mice, including changes in serum cytokines, chemokines, and colony-stimulating factors. In addition, weekly dosing of PCPS/STAT3 siRNA for four weeks did not cause signs of subacute toxicity based on changes in body weight, hematology, blood chemistry, and major organ histology."
According to the news reporters, the research concluded: "Collectively, the results suggest that we have developed a safe vehicle for effective delivery of gene silencing agents."
For more information on this research see: High Capacity Nanoporous Silicon Carrier for Systemic Delivery of Gene Silencing Therapeutics. ACS Nano, 2013;7(11):9867-9880. ACS Nano can be contacted at: Amer Chemical Soc, 1155 16TH St, NW, Washington, DC 20036, USA. (American Chemical Society - www.acs.org; ACS Nano - www.pubs.acs.org/journal/ancac3)
Our news correspondents report that additional information may be obtained by contacting J.L. Shen, Weill Cornell Med College, Dept. of Cell & Dev Biol, New York, NY 10065, United States. Additional authors for this research include R. Xu, J.H. Mai, H.C. Kim, X.J. Guo, G.T. Qin, Y. Yang, J. Wolfram, C.F. Mu, X.J. Xia, J.H. Gu, X.W. Liu, Z.W. Mao, M. Ferrari and H.F. Shen (see also Silicon).
Keywords for this news article include: Cancer, Silicon, Oncology, Treatment, Nanoporous, Therapeutics, New York City, United States, Nanotechnology, Emerging Technologies, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC